September 10, 2021
40 min listen
Save
Innovative Technology and Personalized Cancer Care with Lance Baldo, MD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines.
- Welcome to another exciting episode of Oncology Overdrive :13
- About Baldo :17
- The interview 1:20
- Tell me about your journey 1:38
- Did you question your decision to leave clinical practice for an entrepreneurial venture? 2:36
- What does Adaptive Biotechnologies do? 3:43
- What is Minimal Residual Disease (MRD) testing and how is it used? 4:27
- Are you looking only at hematologic malignancies? 5:35
- How are experts using MRD testing in clinical practice? 6:31
- Why do you think MRD testing is important in treating cancers? 7:24
- Is Adaptive working on drug discovery and development related to MRD testing? 9:20
- Personalized care and how real life feels like science fiction 12:02
- Doing what’s best for the patient 15:33
- Tell me about T-cell receptor profiling 18:02
- Tell me about neo-antigen-based therapy 21:10
- Are these types of technologies available outside of large, academic institutions? 22:49
- Has COVID impacted the way you and your team think about implementing therapies and innovation? 25:03
- Do you think what we’ve learned over the last year will help with the creation of future cancer vaccines? 29:59
- If we spoke again in 10 years, what would you hope to have done? 31:25
- Baldo’s take-home message 37:42
- Where to find Baldo 38:57
Lance Baldo, MD, is chief medical officer of Adaptive Biotechnologies.
We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baldo can be reached on LinkedIn, via email at lbaldo@adaptivebiotech.com and at www.adaptivebiotech.com.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Baldo is chief medical officer of Adaptive Biotechnologies. Jain reports she is a paid freelance writer for Lippincott.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
